Drug intelligence / Profile preview

Tongfeng Wan

Development stage: Unknown
Lead developer: Changchun University of Chinese Medicine
Administration: Oral

Overview

Tongfeng Wan is a traditional Chinese medicine (TCM) formulation developed by the Changchun University of Chinese Medicine for the treatment of acute gouty arthritis. In TCM theory, it is specifically indicated for patients presenting with the pattern of rheumatism with constrained heat. The drug is formulated as a pill (Wan) for oral administration. Clinical evaluation has focused on its efficacy and safety in reducing joint pain and inflammation during acute gout flares compared to placebo in randomized, double-blind trials in China.

Beyond the preview

Go deeper on Tongfeng Wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tongfeng Wan.

Explore the full profile